STOCK TITAN
  1. Home
  2. Sec-filings
  3. CUE
  4. [Form 4] Cue Biopharma, Inc. Insider Trading Activity

Cue Biopharma (CUE) director awarded 1,626 stock options at $21.90 strike

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Cue Biopharma, Inc. reported that director Daniel A. Camardo received a grant of stock options covering 1,626 shares of common stock. The options have an exercise price of $21.90 per share and expire on May 29, 2036.

The award vests over three years, with one-third vesting on the first anniversary of the grant date and the remaining two-thirds vesting in eight equal quarterly installments. Following this grant, Camardo holds stock options for 1,626 underlying shares directly as reported in this filing.

Positive

  • None.

Negative

  • None.
Insider Camardo Daniel A.
Role null
Type Security Shares Price Value
Grant/Award Stock Option (Right to Buy) 1,626 $0.00 --
Holdings After Transaction: Stock Option (Right to Buy) — 1,626 shares (Direct, null)
Footnotes (1)
  1. [object Object]
Options granted 1,626 options Stock Option (Right to Buy) grant
Exercise price $21.90 per share Stock option exercise price
Options after grant 1,626 options Total derivative holdings following transaction
Option expiration May 29, 2036 Expiration date of options
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
exercise price financial
"conversion_or_exercise_price: 21.9000"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
Grant, award, or other acquisition financial
"transaction_code_description: Grant, award, or other acquisition"
vest over three years financial
"The shares underlying the option are scheduled to vest over three years"
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Camardo Daniel A.
(Last)(First)(Middle)
C/O CUE BIOPHARMA, INC.
40 GUEST STREET
(Street)
BOSTON MASSACHUSETTS 02135
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Cue Biopharma, Inc. [ CUE ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/30/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$21.905/30/2026A1,626 (1)05/29/2036Common Stock1,626$01,626D
Explanation of Responses:
1. The shares underlying the option are scheduled to vest over three years with one-third vesting on the one-year anniversary of the grant date and the balance vesting in eight equal quarterly installments.
/s/ Michael Meluzio, Attorney-in-Fact06/08/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Daniel A. Camardo receive in this Cue Biopharma (CUE) Form 4 filing?

Daniel A. Camardo received a grant of stock options for 1,626 shares of Cue Biopharma common stock. These options are a compensation award, not an open‑market purchase, and give him the right to buy shares at a fixed exercise price.

What is the exercise price of Daniel Camardo’s Cue Biopharma (CUE) stock options?

The stock options granted to Daniel Camardo have an exercise price of $21.90 per share. This means he can buy Cue Biopharma common stock at $21.90 per share once the options vest, regardless of the future market price.

How do Daniel Camardo’s Cue Biopharma (CUE) options vest over time?

The options vest over three years. One‑third vests on the one‑year anniversary of the grant date, and the remaining two‑thirds vest in eight equal quarterly installments afterward, aligning the award with longer‑term service at Cue Biopharma.

When do Daniel Camardo’s Cue Biopharma (CUE) stock options expire?

The options are scheduled to expire on May 29, 2036. After that date, any unexercised options will lapse, so they must be exercised before expiration if he chooses to purchase the underlying common shares.

How many Cue Biopharma (CUE) options does Daniel Camardo hold after this grant?

After this grant, Daniel Camardo holds stock options covering 1,626 shares of Cue Biopharma common stock. This total reflects the options reported in this filing as his direct derivative holdings following the transaction.

Is Daniel Camardo’s Cue Biopharma (CUE) option grant an insider purchase or compensation award?

The transaction is a compensation‑related grant or award, not an open‑market purchase. It is reported with transaction code A, meaning a grant, award, or other acquisition of stock options rather than buying shares on the market.